Digital model for predicting the risk of developing acute decompensated heart failure

Rational Pharmacotherapy in Cardiology, Journal Year: 2024, Volume and Issue: 20(3), P. 309 - 315

Published: June 18, 2024

Aim . Development and external validation of a risk prediction model for acute decompensated heart failure (ADHF) in patients with low left ventricular ejection fraction. Material methods The development group was represented by reduced fraction (HFrEF) included registry observational study from 2015 to 2019, total 260 patients, age 59 (53; 66) years, 214 (82.3%) — men. External the carried out cohort independent prospective observation 94 HFrEF same period 2020 2021, median 66 (52;73) which 73 (77.6%) were follow-up 4.6 (2.3; 4.9) years internal group, 2.5 (1.7; 2.9) group. Data obtained on status causes death, frequency hospitalizations ADHF. actual predicted incidence ADHF using evaluated prognostic compared. Results During developed 69 (26.5%) 47 (18.1%) died due regression LA enlargement more than 45 mm, male gender, less 35%, absence renin-angiotensin system blocker amiodarone. When performing ROC analysis, area under curve (AUC) created 0.8, sensitivity 69.2%, specificity 80%, accuracy 75.3%. In 34 (36.2%) cases registered; mortality 15.9%, is comparable (p > 0.05). diagnostic value during showed be high results group: 73.3%, 82.5%, 76.1%, (p=0.102, McNeil test). Conclusion has sufficient statistical power predict long term, confirmed validation.

Language: Английский

Developing the system of quality measures for medical care assessment in patients with chronic heart failure: methodology and criteria (review)

Saratov Journal of Medical Scientific Research, Journal Year: 2024, Volume and Issue: 20(4), P. 425 - 435

Published: Dec. 31, 2024

Objective: To develop a system of quality measures for monitoring the process and outcome medical care in patients with chronic heart failure (CHF) real clinical practice. Review methodology. The procedure selecting indicators to monitor treatment cardiological proposed by О M. Posnenkova (2013) was applied. An analysis Russian Ministry Health's guidelines on CHF (2024) conducted determine characteristics planned outcomes key proven impact outcomes. A systematic literature review using PRISMA methodology performed identify therapeutic interventions that achievement results real-world PubMed eLibrary databases were used. search depth from 2020 2024. Twenty-five sources selected. Conclusion. In practice it is advisable assess: 1) proportion HF reduced ejection fraction (EF) who have been prescribed quad-riple therapy (angiotensin-converting enzyme inhibitor/angiotensin receptor/angiotensin receptor neprilysin inhibitors + beta-blockers aldosterone antagonists sodium/glucose cotransporter 2 inhibitors); 2) preserved EF mildly inhibitors; 3) without adverse events (hospitalizations due or death) over past 12 months.

Language: Английский